オプションチェーンは、Replimune Groupの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Replimune Groupの市場センチメントを評価します。.

Replimune Group (NASDAQ:REPL) 株価情報, オプションチェーン

Replimune Group

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Replimune Group Inc

REPLENISH NUTRIENTS HLDG by REPLENISH NUTRIENTS HLDG CORP.

Replenish Nutrients Holding Corp

REPLICEL LIFE SCIENCE ORD by RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc

Repligen Corp

Reply SpA

WIIM

SPGI

S&P Global shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY25 revenue guidance above estimates. The company also authorized a $4.3 billion share repurchase program.

D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) with a Buy and maintains $5 price target.

News

Price Target

Analyst Ratings

HOTH

D. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target

Piper Sandler analyst Alexander Goldfarb maintains AvalonBay Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>) with a Overweight and lowers the price target from $270 to $265.

Piper Sandler Maintains Overweight on AvalonBay Communities, Lowers Price Target to $265

TRNR

Interactive Strength To Acquire Sportstech Holding; To Acquire 99% Of Sportstech In All-Stock Transaction With Initial Consideration Of $15M In Non-Voting Convertible Preferred Stock

Canadian Prime Minister Justin Trudeau on Tuesday highlighted the adverse effects of the U.S. steel and aluminum tariffs and warned of a strong response if required.
What Happened: Trudeau criticized the recent tariffs calling them &#8220;Unacceptable&#8221; and said &#8220;Canadians will stand up strongly and firmly if we need to,&#8221; reported Reuters.
On Monday, U.S. President Donald Trump signed orders to increase tariffs on <a href="https://www.benzinga.com/markets/equities/25/02/43613133/trumps-25-tarrifs-a-self-inflicted-wound-says-economist-amid-warnings-of-fewer-american-jobs-peter-schiff-says-youll-pay-more-for-cars-and-homes">steel and aluminum imports to 25%</a> without exceptions. This decision, effective Mar 4, intended to boost the struggling industry, could escalate into a wider trade conflict.
SEE ALSO: <a href="https://www.benzinga.com/25/02/43616261/trumps-punitive-tariffs-could-lead-to-us-job-losses-warns-former-ambassadorwere-in-for-a-bit-of-bad-news-in-the-near-term">Trump&#8217;s &#8216;Punitive&#8217; Tariffs Could Lead To US Job Losses, Warns Former Envoy: &#8216;We&#8217;re In For A Bit Of Bad News In The Near Term&#8217;</a>
Why It Matters: This development comes amid escalating tensions between the two nations. Earlier this month, Trudeau expressed concerns over Trump&#8217;s threat to annex Canada. He suggested that Trump&#8217;s interest in making <a href="https://www.benzinga.com/25/02/43582659/trump-says-canada-much-better-off-being-the-51st-state-the-border-with-us-is-just-a-line">Canada the &#8220;51st state&#8221;</a> was driven by a desire to access the country&#8217;s critical minerals. According to&nbsp;the American Iron and Steel Institute, approximately 80% of U.S. primary aluminum imports were from Canada. 
President of the Canadian Labour Congress, Bea Bruske, recalled Trump's previous steel and aluminum tariffs and stated that it had a "devastating impact" on the workers in the country. "Thousands of workers faced layoffs and uncertainty, and the effects rippled across manufacturing, construction and supply chains," stated Bruske.
Minister of Innovation, Science and Industry of Canada, François-Philippe Champagne, called the U.S. tariffs &#8216;totally unjustified&#8217; and stated, &#8220;We are consulting with our international partners as we examine the details. Our response will be clear and calibrated.&#8221;
Trump&#8217;s tariffs on steel and aluminum are set to ripple across key U.S. industries, driving up costs for manufacturers and consumers alike. The automotive sector, including Ford (NYSE F), General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), and Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), faces higher production expenses, while aerospace giants like Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) and Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) may see increased material costs. The construction and infrastructure industry is also expected to feel the impact. According to <a href="https://www.barrons.com/articles/trump-steel-tariffs-car-prices-707e1af4">Barron&#8217;s</a>, the tariffs could add as much as $2,000 to the price of a new car.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/news/25/02/43543459/i-love-canada-more-than-i-love-spotify-canadians-are-canceling-netflix-amazon-disney-and-spotify-en-masse-despite-the-tariff-pause">&#8216;I Love Canada More Than I Love Spotify&#8217;—Canadians Are Canceling Netflix, Amazon, Disney+, And Spotify En Masse, Despite The Tariff Pause</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Economics

Markets

TSLA

Justin Trudeau Slams 'Unacceptable' US Tariffs After Trump Imposes 25% Levy On Metal Imports : 'Canadians Will Stand Up Strongly And Firmly If We Need To'

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

LMFA

LM Funding America Mined 8 Bitcoin In Jan.

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">91.03</td>
<td align="right">0.52</td>
<td align="right">0.57</td>
<td>27.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.01</td>
<td align="right">0.17</td>
<td align="right">0.21</td>
<td>749</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">235.50</td>
<td align="right">-0.72</td>
<td align="right">-0.31</td>
<td>19.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">103.00</td>
<td align="right">-0.20</td>
<td align="right">-0.20</td>
<td>618</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">78.89</td>
<td align="right">-0.10</td>
<td align="right">-0.13</td>
<td>1.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">138.51</td>
<td align="right">-0.05</td>
<td align="right">-0.04</td>
<td>844</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.40</td>
<td align="right">-0.01</td>
<td align="right">-0.02</td>
<td>42.8K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

Leading And Lagging Sectors For February 11, 2025

Ecolab shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY25 adjusted EPS guidance above estimates.

Mizuho analyst Vijay Rakesh maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Outperform and lowers the price target from $85 to $71.

Mizuho Maintains Outperform on ON Semiconductor, Lowers Price Target to $71

INAB

IN8bio shares are trading higher after the company announced new clinical data from the ongoing Phase 1 investigator-sponsored trial of INB-100.

Phillips 66 shares are trading higher after activist investor Elliott Investment Management disclosed a $2.5 billion stake in the company.

JP Morgan analyst Mark Murphy maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Overweight and raises the price target from $635 to $725.

HUBS

JP Morgan Maintains Overweight on HubSpot, Raises Price Target to $725

Buybacks

SRTS

Sensus Healthcare Resumes $3M Share Repurchase Program

Contracts

ROLR

High Roller Enters Into A Strategic Partnership With Yggdrasil

WESCO International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) reported fourth-quarter adjusted earnings per share of $3.16,<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43617413/wesco-international-reports-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener"> missing the street view of $3.23</a>. Quarterly sales of $5.50 billion outpaced the analyst consensus estimate of $5.41 billion.
The fourth-quarter reported net sales increased by 0.5% year-over-year, with organic sales rising 2.4% year-over-year and 1.7% sequentially.
&#8220;We are pleased with our return to sales growth in the fourth quarter sparked by more than 70% growth year-over-year in our global Data Center business, 20% growth in Broadband Solutions, and renewed positive sales momentum in Electrical and Electronic Solutions,&#8221; said&nbsp;John Engel, Chairman, President, and CEO.
Engel stated that financial leverage remained stable at 2.9x trailing twelve-month adjusted EBITDA, highlighting a $431 million reduction in net debt and $425 million in share repurchases last year.
Also Read:<a target="_blank" href="https://www.benzinga.com/markets/25/02/43618710/smci-stock-falls-nearly-4-in-tuesday-pre-market-as-investors-await-an-update-on-delayed-filing" rel="noreferrer noopener"> SMCI Stock Falls Nearly 4% In Tuesday Pre-Market As Investors Await An Update On Delayed Filing</a>
The CEO also mentioned the strengthening of the portfolio through the divestiture of the integrated supply business and acquisitions of three services-based businesses, including Ascent.
Looking ahead to 2025, the company noted that the pipeline of strategic acquisitions remains strong and aligned with the goal of expanding service offerings to customers.
WESCO exited the quarter with cash and equivalents worth $702.6 million.
Outlook: In 2025, the company expects organic sales to grow 2.5% to 6.5% and the operating margin to expand, as all three business units to deliver profitable growth.
WESCO expects to generate&nbsp;$600&nbsp;million to&nbsp;$800 million&nbsp;of free cash flow and plans to increase the common stock dividend by 10% again this year to&nbsp;$1.82&nbsp;per share while continuing its share buyback program.&nbsp;
Price Action: WCC shares are trading lower by 2.45% to $188.76 premarket at last check Tuesday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43591520/dell-vs-hp-ai-server-jpmorgan-pick" target="_blank" rel="noreferrer noopener">Wall Street's AI Server Darling? JPMorgan Says It's Still Dell</a></li>
</ul>

Earnings

Equities

Guidance

General

WESCO Q4: EPS Miss, Flat Sales, Effective Working Capital Management And More

LCTX

Lineage Initiates The DOSED Clinical Study Of OPC1 In Spinal Cord Injury

AREB

American Rebel Holdings Regains NASDAQ Compliance

JP Morgan analyst Harlan Sur maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Neutral and lowers the price target from $88 to $60.

JP Morgan Maintains Neutral on ON Semiconductor, Lowers Price Target to $60

Supply agreement enables a refreshed Massey Ferguson utility tractor range

AGCO

AGCO And SDF Partner To Strengthen Global Position In Low-Mid Horsepower Tractor Segment

Needham analyst Quinn Bolton reiterates Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Buy and maintains $140 price target.

Reiteration

ALAB

Needham Reiterates Buy on Astera Labs, Maintains $140 Price Target

Analyst Song holds a group dinner meeting in New York on December 17 at 6 pm hosted by Jefferies. Published first on TheFly – the ultimate source f...

Replimune management to meet with Jefferies

Replimune (REPL) Group announced that the first patients have been enrolled in studies evaluating RP2 in two different settings: checkpoint naive m...

Replimune announces RP2 development program advances

Evan Seigerman, an analyst from BMO Capital, has initiated a new Buy rating on Replimune Group (REPL). Evan Seigerman has given his Buy rating due ...

Replimune Group's Strategic Advances Highlight Promising Potential in Oncolytic Virus Therapy

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Replimune Group (REPL – Research Report), with a price target of ...

Replimune Group (REPL) Receives a Buy from Barclays

Replimune announces priority review for its melanoma treatment

Biggest stock movers Tuesday: RDW, CAN, EOLS, REPL, EDU, FTAI and more

H.C. Wainwright analyst Robert Burns raised the firm's price target on Replimune (REPL) to $21 from $17 and keeps a Buy rating on the shares. The f...

Replimune price target raised to $21 from $17 at H.C. Wainwright

BMO Capital analyst Evan Seigerman raised the firm's price target on Replimune (REPL) to $27 from $18 and keeps an Outperform rating on the shares....

Replimune price target raised to $27 from $18 at BMO Capital

Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on REPL stock, giving a Buy rating yesterday. Jonathan Chang has given ...

Replimune Group's Promising Outlook: FDA Priority Review and Positive Trial Data Support Buy Rating

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Replimune Group (REPL – Research Report), Pliant The...

Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Pliant Therapeutics (PLRX) and Immunovant (IMVT)

EOLS

FTAI

IMVT

NWOEF

PLRX

REPL

VATE

Press Releases

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

Health Care

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Announces Proposed Public Offering

Replimune Announces Pricing of Upsized Public Offering

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials

Comments

Replimune Group

Replimune Group (REPL) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル